Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome
DOI:
https://doi.org/10.1590/s2175-979020201000X22e19868Keywords:
Statins, Acute coronary syndrome, Drug-drug interactions, Risk factorsAbstract
The aim of our study was to assess risk factors for potential drug-drug interactions (pDDIs) of statins across different phases of treatment of acute coronary syndrome (ACS) patients: from the point of first medical contact to the coronary angiography (first phase), after coronary angiography to the last day of hospitalization (second phase) and at discharge from hospital (third phase). This was a post hoc analysis of the data collected during the retrospective observational cohort study conducted at the Clinic for Cardiology of the Clinical Centre Kragujevac, Serbia. Patients prescribed statins were identified from the original study population: 156, 240 and 236 patients for the first, second and third phases, respectively. At least one statin pDDI was present in 113 (72.4%), 161 (67.1%) and 139 (58.9%) patients in the first, second and third phases, respectively. Heart failure, arrhythmias after ACS, CRP, triglycerides, length of hospitalization, number of prescribed drugs, antiarrhythmic drugs, and clopidogrel seem to increase the risk of statin pDDIs in at least one treatment phase. Physicians should be vigilant to the possibility of statin pDDIs in ACS patients who have factors that may increase their rate.
Downloads
References
Akimoto H, Negishi A, Oshima S, Okita M, Numajiri S, Inoue N, et al. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Pharmacol Res Perspect. 2018;6(6):e00439.
Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25-37.
Causevic-Ramosevac A, Semiz S. Drug interactions with statins. Acta Pharm. 2013;63(3):277-93.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
de Lima TAM, de Godoy MF. Drug-drug interactions in prescriptions for hospitalized elderly with Acute Coronary Syndrome. Rev Eletrônica Enferm. 2017;19:a24.
del Val Martin D, Sanmartín Fernández M, Zamorano Gómez JL. Biomarkers in acute coronary syndrome. IJC Metab Endocr. 2015;8:20-3.
Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24(5):429-40.
Gavronski M, Volmer D, Hartikainen S, Zharkovsky A. Potential drug interactions with statins: Estonian register- based study. Open Med Wars. 2015;10(1):254-60.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-77.
Jozic T, Terzic B, Mitrovic P, Kostic J, Milanov M, Stojanovic M, et al. Combined statin-fibrate therapy- induced rhabdomyolysis: Case report. Hosp Pharmacol - Int Multidiscip J. 2014;1(1):22-6.
Kellick KA, Bottorff M, Toth PP, The National Lipid Association’s Safety Task Force. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol. 2014;8(3 Suppl):S30-46.
Kovačević M, Vezmar Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross- sectional study. Int J Clin Pract. 2017;71(10):e13005.
Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107(1):32-7.
Li XP, Gong HR, Huang XS, Huang WY, Zhao SP. The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome. Lipids Health Dis. 2013;12:133.
Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug- drug interactions. Expert Opin Drug Saf . 2012;11(1):83-94.
Morival C, Westerlynck R, Bouzillé G, Cuggia M, Le Corre P. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur J Clin Pharmacol. 2018;74(4):525-34.
Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart. 2005;91(1):23-6.
Nordmann A, Schwartz G, Vale N, Bucher HC, Briel M. Cochrane corner: early statin therapy in acute coronary syndromes-what is the clinical benefit? Heart. 2016;102(9):653-4.
Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 2013;6(12):1275-81.
Park Y, Jeong YH, Tantry US, Ahn JH, Kwon TJ, Park JR, et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J . 2012;33(17):2151-62.
Pejčić AV, Janković SM, Davidović G. Drug-drug interactions in patients with acute coronary syndrome across phases of treatment. Intern Emerg Med. 2019;14(3):411-22.
Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28(3):263-75.
Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J . 2016;37(3):267-315.
Samardzic I, Benkovic I, Vrca VB. Incidence of statin-drug interactions in Croatian community pharmacy. Pharmazie. 2017;72(3):187-91.
Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015;38(2):197-206.
Steinhubl SR, Akers WS. Clopidogrel-statin interaction: a mountain or a mole hill? Am Heart J. 2006;152(2):200-3.
Thotakura S, Singh A, Khera K, Chauhan S, Devasia T. Atorvastatin-induced hepatotoxicity, increased by clopidogrel stress on CYP450 Enzyme: Understanding the mechanism through a case. J Appl Pharm Sci. 2018;8(4):168-170.
Todorović ZM, Đukanović NB, Obradović SD, Protić DD, Ostojić MČ. Clopidogrel-statin interaction: A missing links. Hosp Pharmacol - Int Multidiscip J . 2016;3(2):395-401.
Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468-95.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
